ALK/EGFR Inhibitor AP26113 - Dr. Ross Camidge

Description: For more updates visit

Dr. Ross Camidge with an update on ECC 2013 Abstract #3401. AP26113 has promising anti-tumor activity in pts with ALK+ NSCLC and other ALK+ tumors, with initial evidence of activity in EGFRm pts, and is generally well tolerated. Phase 2 will begin after the recommended phase 2 dose is determined. Cohorts will include: crizotinib-naive NSCLC; crizotinib-resistant NSCLC; EGFR TKI-resistant NSCLC; other tumors. NCT01449461.
Shared By : oncologyeducation
Posted on : 10/07/13
Added : 6 years ago
Category : Other